Standard BioTools Inc
NASDAQ:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Standard BioTools Inc
NASDAQ:LAB
|
US |
|
Labrador Gold Corp
XTSX:LAB
|
CA |
|
CP Axtra PCL
SET:CPAXT
|
TH |
|
Scope Industries
OTC:SCPJ
|
US |
|
V
|
Vinci SA
SWB:SQU
|
FR |
|
I
|
ITV PLC
XMUN:IJ7
|
UK |
|
A
|
Autozone Inc
DUS:AZ5
|
US |
|
P
|
Prosperity Weaving Mills Ltd
KAR:PRWM
|
PK |
|
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
|
US |
|
A
|
Aeon Thana Sinsap Thailand PCL
SET:AEONTS
|
TH |
|
E
|
EUROKAI GmbH & Co KgaA
XHAM:EUK2
|
DE |
Earnings Calls
Last Earnings Call
Revenue: Q1 2025 revenue was $40.8 million, down 10% year-over-year and in line with expectations.
Guidance Maintained: Full year 2025 revenue guidance remains unchanged at $165 million to $175 million, with revenue expected to be weighted more toward the second half of the year.
Cost Reductions: Non-GAAP operating expenses decreased by 22% year-over-year, driven by $10 million in additional cost reductions this quarter, bringing total annualized savings since the SomaLogic merger to $90 million.
Gross Margin: Non-GAAP gross margin was 53.2%, down from 56.2% last year, mainly due to lower volumes and product mix.
Cash Position: Ended Q1 with $261 million in cash and equivalents and no material debt, with significantly reduced cash burn versus last year.
Instrument Sales: Instrument revenue grew 24% year-over-year in Q1, led by continued success of the Hyperion XTi platform.
Academic Headwinds: Mid-teens percentage decline expected in Americas academic revenue, with ongoing academic funding delays and spending curbs.
M&A Focus: Management confirms a disciplined M&A approach, noting a robust pipeline of potential deals but high standards for execution.